- Home
- ARBK vs ICCC Comparison
ARBK vs ICCC Comparison
Compare ARBK & ICCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARBK
- ICCC
- Stock Information
- Founded
- ARBK 2017
- ICCC 1982
- Country
- ARBK United Kingdom
- ICCC United States
- Employees
- ARBK N/A
- ICCC N/A
- Industry
- ARBK Finance: Consumer Services
- ICCC Biotechnology: Pharmaceutical Preparations
- Sector
- ARBK Finance
- ICCC Health Care
- Exchange
- ARBK Nasdaq
- ICCC Nasdaq
- Market Cap
- ARBK 42.6M
- ICCC 45.9M
- IPO Year
- ARBK 2021
- ICCC 1987
- Fundamental
- Price
- ARBK $0.59
- ICCC $5.50
- Analyst Decision
- ARBK Hold
- ICCC
- Analyst Count
- ARBK 2
- ICCC 0
- Target Price
- ARBK $1.45
- ICCC N/A
- AVG Volume (30 Days)
- ARBK 574.5K
- ICCC 10.0K
- Earning Date
- ARBK 11-20-2024
- ICCC 02-25-2025
- Dividend Yield
- ARBK N/A
- ICCC N/A
- EPS Growth
- ARBK N/A
- ICCC N/A
- EPS
- ARBK N/A
- ICCC N/A
- Revenue
- ARBK $52,868,000.00
- ICCC $23,838,001.00
- Revenue This Year
- ARBK N/A
- ICCC N/A
- Revenue Next Year
- ARBK $175.58
- ICCC N/A
- P/E Ratio
- ARBK N/A
- ICCC N/A
- Revenue Growth
- ARBK 18.91
- ICCC 46.37
- 52 Week Low
- ARBK $0.52
- ICCC $3.34
- 52 Week High
- ARBK $2.92
- ICCC $5.82
- Technical
- Relative Strength Index (RSI)
- ARBK 39.45
- ICCC 62.66
- Support Level
- ARBK $0.55
- ICCC $4.86
- Resistance Level
- ARBK $0.64
- ICCC $5.50
- Average True Range (ATR)
- ARBK 0.06
- ICCC 0.35
- MACD
- ARBK 0.01
- ICCC -0.01
- Stochastic Oscillator
- ARBK 31.88
- ICCC 100.00
About ARBK Argo Blockchain plc
Argo Blockchain PLC is a data center business that provides a powerful and efficient platform for cryptocurrency mining operations. The company has operations in strategic locations in North America.
About ICCC ImmuCell Corporation
ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company operates in two business segment. The Scours segment is dedicated to manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows, which is regulated by the United States Food and Drug Administration (FDA). The company generates the majority of its revenue from the Scours segment.